TY - JOUR
T1 - Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non–Small-cell Lung Cancer
AU - Kim, Edward
AU - Feldman, Rebecca
AU - Wistuba, Ignacio I.
N1 - Funding Information:
The authors met the criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and received no direct compensation related to the development of the report. Writing, editorial support, and formatting assistance were provided by Lauren Fink, PhD, of MedErgy, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). BIPI was given the opportunity to review the manuscript for medical and scientific accuracy and intellectual property considerations.
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/3
Y1 - 2018/3
N2 - Mutations in the epidermal growth factor receptor (EGFR) are important drivers of non–small-cell lung cancer (NSCLC) and have led to the emergence of EGFR-targeted therapies as critical treatment options for NSCLC. Although these agents have shown clinical activity in NSCLC patients, acquired resistance to EGFR-targeted agents is inevitable. Therefore, the ability to conveniently biopsy patient tumors is of increasing importance as new mechanisms of resistance and agents to target these resistance mutations are identified. Rapid and accurate EGFR mutational testing of patient biopsy specimens, including liquid biopsy specimens, allows for the identification of potentially actionable mutations that could guide treatment. In the present review, we discuss the various methods and best practices for tumor sampling and EGFR mutational testing in NSCLC.
AB - Mutations in the epidermal growth factor receptor (EGFR) are important drivers of non–small-cell lung cancer (NSCLC) and have led to the emergence of EGFR-targeted therapies as critical treatment options for NSCLC. Although these agents have shown clinical activity in NSCLC patients, acquired resistance to EGFR-targeted agents is inevitable. Therefore, the ability to conveniently biopsy patient tumors is of increasing importance as new mechanisms of resistance and agents to target these resistance mutations are identified. Rapid and accurate EGFR mutational testing of patient biopsy specimens, including liquid biopsy specimens, allows for the identification of potentially actionable mutations that could guide treatment. In the present review, we discuss the various methods and best practices for tumor sampling and EGFR mutational testing in NSCLC.
KW - Circulating-free tumor DNA
KW - Epidermal growth factor receptor
KW - Mutational testing
KW - NSCLC
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85029528918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029528918&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2017.08.001
DO - 10.1016/j.cllc.2017.08.001
M3 - Review article
C2 - 28935493
AN - SCOPUS:85029528918
SN - 1525-7304
VL - 19
SP - 105
EP - 114
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 2
ER -